Unlike BRAF-mutant melanomas, which respond to BRAF/MEK inhibition, MEK inhibition alone or in combination with immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, has provided limited clinical benefit in NRAS-mutant melanoma, highlighting the urgent need for novel therapeutic strategies. Here, MAP2K7 is linked to melanoma.